Skip to content
Disclosery

Syncona Portfolio Ltd

Follow

13F filer, CIK 1725042, St Peter Port, Guernsey, United Kingdom

Syncona Portfolio Ltd reported $52,969,955 across 3 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-06.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-001070

Period
2024-12-31
Reported value
$53M
Holdings
3
Top 10 weight
100%
New
0
Sold out
0

Part of the filer group Syncona Portfolio Ltd

How groups are built

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AUTLreduced-1,913,904-$4.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0000950123-25-001070, largest first. % of portfolio is the value over $52,969,955, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AUTLAUTOLUS THERAPEUTICS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 18,554,624 shares; 2024Q4: 16,640,720 shares 16,640,720$39.1M73.83%-1,913,904Timeline
ACHILLES THERAPEUTICS PL-ADRACHILLES THERAPEUTICS PL-ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,086,909 shares; 2024Q4: 11,086,909 shares 11,086,909$12.6M23.86%0
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,213,056 shares; 2024Q4: 1,213,056 shares 1,213,056$1.23M2.31%0Timeline

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-001070 base2025-02-06acceptance time not in the bulk data set